CYRSIFI
Live / Applied — Withdrawn from publication (as of 21 Aug 2026)
What this means for you
Not registered yet, but its 18 Feb 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99658232
- Mark type
- Word mark
- Filed
- 18 Feb 2026
- Published for opposition
- 08 Sept 2026
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 21 Aug 2026 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 12 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 15 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 15 Jun 2026 — NON-FINAL ACTION E-MAILED
- 15 Jun 2026 — NON-FINAL ACTION WRITTEN
- 09 Jun 2026 — ASSIGNED TO EXAMINER
- 18 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 18 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Feb 2026 — NEW APPLICATION ENTERED